11 April 2019
Visiongain has published a new pharma report Global Blood Cancer Market Forecast to 2028: Immunotherapy, Chemotherapy, Targeted Therapy.
The global blood cancer market reached $24bn in 2018 and is estimated to grow at a CAGR of 6.4% in the first half of the forecast period. Chemotherapy held 44% of the market in 2018. The changing demographics of the world population, developing infrastructure, emerging economies, consumer spending behaviour, per capita income, macroeconomic factors, rising GDPs, and the reformation in laws and regulations are trend setting factors, which will affect the market.
This report profiled the selected companies: Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb (BMS), Celgene and other companies.
The lead analyst commented that "Chemotherapy will continue to be the largest segment for therapy of cancer; however, the huge effort for a breakthrough in cancer treatment will result in the growth of targeted cell therapy as well as immunotherapy segments. High income countries will see more growth in this novel type of therapy when compared to the developing nations due to the high cost of the treatment. Blood cancer market is expected to grow as the number of cases would increase due to non-availability of the perfect treatment options."
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.
10 August 2020
Biosimilars will be changing the biologics market in the long term. But whether it does it for the better or the worse will depend on how the producers of biologics respond to their market presence.
06 August 2020
Conceptually, it is clear for all stakeholders in the health care segment as well in the biotechnological sector the benefits are evident since it will improve the speed and accuracy of diagnostics or analysis.
05 August 2020
With the threat of growing number of patients due to the COVID-19 infections, the supply chain trends are looking at a shift with no contact and social distancing policies.